放射性碘难治性分化型甲状腺癌:分类更新时机已到
该综述讨论放射性碘难治性分化型甲状腺癌(DTC)现有主要分类、判定前需考虑的因素、管理策略及分类修订方向。作者指出现有分类虽有价值但非绝对,不应仅因患者符合某条分类就判定为碘难治,应个体化管理并建立多组织常设委员会监督分类更新。
要点
- 现有碘难治性DTC分类有价值但非绝对,不应仅凭符合分类条目即判定难治。
- 判定碘难治前需充分理解各分类的局限性和混杂因素,结合个体情况评估。
- 建议建立多组织常设委员会监督和协助碘难治性DTC分类的更新。
核心结论
- 碘难治性DTC分类将继续演变,需更多研究、医生更好理解分类局限性及新药改变碘摄取。
- 现分类虽有价值但非神圣不可变,不应仅因符合分类条目就判定患者DTC为碘难治。
研究设计与样本
- 综述,讨论碘难治性DTC现有主要分类、判定前需考虑因素、管理方法及分类修订方向。
主要发现
- 现有碘难治性DTC分类虽有价值,但在个体化管理背景下并非绝对。
- 仅因患者符合一条或多条分类条目,不应按定义或事实判定其DTC为碘难治。
- 需认识各分类的局限性及潜在管理方法,结合影响患者临床情况的多种因素进行个体化诊疗。
临床怎么用
- 临床医生应理解现有碘难治性DTC分类的局限性,结合患者具体情况个体化判断和管理。
- 不应仅凭患者符合某条分类标准就排除其接受可能有益的131I治疗的机会。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: The management of aggressive and progressing metastatic differentiated thyroid cancer (DTC) is very difficult, and the determination as to when such patients are refractory to 131I therapy (e.g., radioiodine refractory) is problematic and controversial. OBJECTIVE: The objective of this review is to discuss (i) the present major classifications of radioiodine refractory disease in DTC, (ii) factors that should be considered before designating a patient's DTC as radioiodine refractory, (iii) potential approaches and caveats to help manage and minimize a patient's exclusion from an 131I therapy that may have potential benefit in patients with aggressive and progressing metastatic DTC, (iv) next steps for revision of the classifications of radioiodine refractory DTC, and (v) areas for future research. SUMMARY: To date, the classifications of radioiodine refractory DTC, although very useful, are not sacrosanct especially in the context of individualized patient management, and merely because a patient meets one or more of the various classifications, one should not consider by definition, fiat, or de facto that that a patient's DTC is radioiodine refractory. Rather, each patient should be individually managed with a good understanding of the limitations of the various classifications and potential approaches to help manage that patient. With awareness of the suggestions and caveats discussed herein and with assessment of the many other factors that affect the patient's specific clinical situation, the managing physician can deliver appropriate individualized patient care. A multi-organizational committee should be established as a standing committee to supervise and assist in the update of the classifications of radioiodine refractory DTC, including discussions of their limitations. CONCLUSION: Classifications to help determine radioiodine refractory disease will continue to evolve as (i) more studies are published, (ii) managing physicians better understand the limitations and confounding factors of present classifications, and (iii) new agents either increase or reestablish 131I uptake.
引用
- Van Nostrand D. Radioiodine Refractory Differentiated Thyroid Cancer: Time to Update the Classifications. Thyroid. 2018. PMID: 30105931. doi:10.1089/thy.2018.0048
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。